TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14610443

Group type: EXPERIMENTAL
Intervention: Participation in Project Read (treatment group)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (no participation in Project Read)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Receiving a videotape on the importance of reading
Number of subjects: 165
Study: 10518845

Group type: COMPARATOR
Intervention: Budesonide inhalation suspension
Number of subjects: 0
Study: 7488804

Group type: EXPERIMENTAL
Intervention: Prolonged emptying of one breast at each feed (experimental group)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Both breasts equally drained at each feed (control group)
Number of subjects: 302
Study: 1834598

Group type: EXPERIMENTAL
Intervention: 2% metronidazole and 5% benzoyl peroxide cream
Number of subjects: 4
Study: 7048920

Group type: EXPERIMENTAL
Intervention: Oral acyclovir (200 mg five times a day for five days)
Number of subjects: 90
Study: 31202211

Group type: EXPERIMENTAL
Intervention: Fib-19-01
Number of subjects: 100

Group type: COMPARATOR
Intervention: Food Supplement (FS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No Supplementary Treatment (NoST)
Number of subjects: 100
Study: 30465349

Group type: EXPERIMENTAL
Intervention: Sandblasting with 50 µm alumina oxide at 0.2 MPa pressure
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Sandblasting with 50 µm alumina oxide at 0.4 MPa pressure
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Sandblasting with 50 µm alumina oxide at 0.6 MPa pressure
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Sandblasting with 100 µm alumina oxide at 0.2 MPa pressure
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Sandblasting with 100 µm alumina oxide at 0.4 MPa pressure
Number of subjects: 63
Study: 26545141

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 2mg/kg loading dose followed by 1mg/kg/day continuous infusion from days 1 to 7
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 24793711

Group type: EXPERIMENTAL
Intervention: 20 mL of 1.5% mepivacaine solution (n=31)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 30 mL of 1.5% mepivacaine solution (n=33)
Number of subjects: 64
Study: 22325367

Group type: EXPERIMENTAL
Intervention: EnSite NavX™ mapping system
Number of subjects: 210

Group type: COMPARATOR
Intervention: Conventional catheter ablation
Number of subjects: 210
Study: 19631515

Group type: EXPERIMENTAL
Intervention: Genistein aglycone (54mg daily)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Genistein aglycone
Number of subjects: 138
Study: 18538112

Group type: EXPERIMENTAL
Intervention: Vildagliptin/metformin fixed-dose combination tablets (50/500 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vildagliptin/metformin fixed-dose combination tablets (50/850 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vildagliptin/metformin fixed-dose combination tablets (50/1,000 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vildagliptin/metformin fixed-dose combination tablets
Number of subjects: 0
Study: 16009687

Group type: EXPERIMENTAL
Intervention: Radiofrequency thermal ablation (RFTA)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Percutaneous ethanol injection (PEI)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Percutaneous acetic acid injection (PAI)
Number of subjects: 187
Study: 12296618

Group type: EXPERIMENTAL
Intervention: Recombinant human activated protein C (Xigris®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 10604045

Group type: EXPERIMENTAL
Intervention: Diclofenac free acid suspension (50 mg)
Number of subjects: 24
Study: 7561229

Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hypnotic relaxation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (suggestion alone, hypnotic induction plus suggestion)
Number of subjects: 32
Study: 1948378

Group type: EXPERIMENTAL
Intervention: Propofol/alfentanil anesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nitrous oxide/alfentanil anesthesia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-pass digital filtering (30-Hz)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Retrospective study
Number of subjects: 20
Study: 6764119

Group type: EXPERIMENTAL
Intervention: Levamisole hydrochloride (150 mg daily for 3 consecutive days every fortnight)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no further treatment until progressive disease)
Number of subjects: 50
Study: 31981236

Group type: EXPERIMENTAL
Intervention: Pain severity assessed during walking using the Western Ontario and McMasters Universities Osteoarthritis Index (no pain = 10; mild pain = 28; moderate pain = 17)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Radiographic disease severity graded by Kellgren and Lawrence scale (KL2 = 29; KL3 = 21; KL4 = 5)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Coordination variability for select joint couplings
Number of subjects: 55
Study: 31654592

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no DSWI)
Number of subjects: 80
Study: 28678148

Group type: EXPERIMENTAL
Intervention: Levosimendan (No-L-group)
Number of subjects: 94

Group type: COMPARATOR
Intervention: No levosimendan (L-group)
Number of subjects: 94
Study: 26498398

Group type: EXPERIMENTAL
Intervention: Long-lasting cerebral vasospasm (LL-CVS) treatment
Number of subjects: 106

Group type: COMPARATOR
Intervention: Regular-lasting cerebral vasospasm (control group)
Number of subjects: 106
Study: 24486425

Group type: EXPERIMENTAL
Intervention: 2 mA tDCS + CCT
Number of subjects: 27

Group type: COMPARATOR
Intervention: sham tDCS + CCT
Number of subjects: 27

Group type: COMPARATOR
Intervention: sham CCT + 2 mA tDCS
Number of subjects: 27
Study: 21892676

Group type: EXPERIMENTAL
Intervention: Supervised weight-bearing jumping exercises and circuit training
Number of subjects: 498

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 498
Study: 19550337

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 microg kg(‐1)) infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fentanyl (1.0 microg kg(‐1)) infusion
Number of subjects: 30
Study: 17559746

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16255132

Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin) as a component of first-line treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuing bevacizumab in subsequent regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetuximab (Erbitux) in standard first-line chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Widely accepted practices in colorectal cancer without direct supportive data
Number of subjects: 0
Study: 12372195

Group type: EXPERIMENTAL
Intervention: Non-invasive continuous positive airways pressure (CPAP) for 18 hours
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional treatment (nebulized epinephrine and humidified oxygen)
Number of subjects: 25
Study: 10334519

Group type: EXPERIMENTAL
Intervention: Fluorouracil (FU) + Folinic acid (Leucovorin, LV)
Number of subjects: 1016

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 1016
Study: 1433587

Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 434
Study: 3894245

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (Prednisolone 1 mg/kg/day for 9 days over 3 cycles)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (Prednisolone)
Number of subjects: 10
Study: 31356713

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: CBT + medication
Number of subjects: 319

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: CAMS remission
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Treatment response and remission
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Baseline self-reported depressive symptoms
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Negative life events
Number of subjects: 319
Study: 28953199

Group type: EXPERIMENTAL
Intervention: Use of hemodynamic information for heart failure management decisions
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Pulmonary artery pressure monitoring system
Number of subjects: 550

Group type: COMPARATOR
Intervention: Control group (no hemodynamic information available)
Number of subjects: 550
Study: 26725133

Group type: EXPERIMENTAL
Intervention: MICA-TKA
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 108
Study: 26335706

Group type: EXPERIMENTAL
Intervention: Palonosetron (0.075 mg i.v.; n = 35)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg i.v.; n = 35)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3 mg i.v.; n = 35)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Overall incidence of PONV
Number of subjects: 105

Group type: COMPARATOR
Intervention: Statistical difference in complete responders
Number of subjects: 105
Study: 24156441

Group type: EXPERIMENTAL
Intervention: Simple mobilization group (5.0‐10.0 µg/(kg·d) rhG‐CSF)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Combined mobilization group (rhG‐CSF + 10 mg dexamethasone for 2‐4 hours before collection)
Number of subjects: 43
Study: 21372623

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - 6 weekly 90-min sessions
Number of subjects: 182

Group type: COMPARATOR
Intervention: Usual medical care (Control)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 182
Study: 18323548

Group type: COMPARATOR
Intervention: Exemestane 25 mg daily
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Combination of exemestane 25 mg daily with celecoxib 400 mg twice daily
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Combination of exemestane and celecoxib
Number of subjects: 111
Study: 16580574

Group type: EXPERIMENTAL
Intervention: Calcium and CLA supplementation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 14521724

Group type: EXPERIMENTAL
Intervention: Roux-en-Y technique (RY)
Number of subjects: 149

Group type: COMPARATOR
Intervention: P pouch with Roux-en-Y reconstruction (PRY)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Jejunal pouch reconstruction according to Hunt-Lawrence technique (HL)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Jejunal pouch original interposition reconstruction (JOP)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Hunt-Lawrence reconstruction technique maintaining duodenal passage (HLD)
Number of subjects: 149
Study: 10741936

Group type: EXPERIMENTAL
Intervention: Rifaximin 600 mg/day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Rifaximin 1200 mg/day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Rifaximin 2400 mg/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 54
Study: 9385176

Group type: EXPERIMENTAL
Intervention: Emollient antibacterial soap
Number of subjects: 84

Group type: COMPARATOR
Intervention: Non-emollient antibacterial soap
Number of subjects: 84
Study: 7714353

Group type: EXPERIMENTAL
Intervention: Pefloxacin added to standard MDT
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard MDT alone
Number of subjects: 20
Study: 3592139

Group type: EXPERIMENTAL
Intervention: Oral prednisolone 7.5 mg daily for 3 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Injection with 2 ml suspension of betamethasone dipropionate and betamethasone disodium phosphate (Diprospan)
Number of subjects: 36
Study: 31072189

Group type: EXPERIMENTAL
Intervention: Multi-treatment response adaptive procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response-adaptive randomization (RAR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cumulative odds ratios
Number of subjects: 0
Study: 29402879

Group type: EXPERIMENTAL
Intervention: HF‐rTMS + TOMT
Number of subjects: 20

Group type: COMPARATOR
Intervention: HF‐rTMS
Number of subjects: 20
Study: 26673107

Group type: EXPERIMENTAL
Intervention: Perceived high cholesterol as 'very serious'
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: High self-efficacy
Number of subjects: 155
Study: 24638238

Group type: EXPERIMENTAL
Intervention: High-dose-rate (HDR) brachytherapy
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Low-dose-rate (LDR) brachytherapy
Number of subjects: 652
Study: 23785909

Group type: EXPERIMENTAL
Intervention: Augmented repair
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-augmented repair
Number of subjects: 0
Study: 20156091

Group type: EXPERIMENTAL
Intervention: EFV/FTC/TDF
Number of subjects: 300

Group type: COMPARATOR
Intervention: SBR
Number of subjects: 300
Study: 18071815

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Small-incision cholecystectomy (SIC)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Minimal invasive procedures (LC and SIC combined)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Converted procedures (non-minimal invasive)
Number of subjects: 257
Study: 16368847

Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver with peak inspiratory pressures up to 50 cm H2O followed by ventilation with 12 cm H2O PEEP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard ventilation with 4 cm H2O PEEP (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver
Number of subjects: 0
Study: 12972958

Group type: EXPERIMENTAL
Intervention: Colonic J-pouch
Number of subjects: 40

Group type: COMPARATOR
Intervention: Coloplasty pouch
Number of subjects: 40
Study: 10380294

Group type: EXPERIMENTAL
Intervention: Fetal heart rate variability in diabetic women
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Umbilical artery peak systolic velocity in diabetic women
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fetal heart rate and umbilical artery time-averaged velocity
Number of subjects: 16

Group type: COMPARATOR
Intervention: Variability in umbilical artery flow velocity
Number of subjects: 16
Study: 8829857

Group type: EXPERIMENTAL
Intervention: 1 mg.ml‐1 of morphine and ketamine (n = 22)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 1 mg.ml‐1 of morphine (n = 20)
Number of subjects: 42
Study: 1729575

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate orally four times a day during hospitalization
Number of subjects: 95

Group type: COMPARATOR
Intervention: No iron supplement (Control group)
Number of subjects: 95
Study: 6727693

Group type: EXPERIMENTAL
Intervention: High oestrogen dose (oestriol and 17 beta‐oestradiol)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Medium oestrogen dose (oestriol and 17 beta‐oestradiol)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Low oestrogen dose (oestriol and 17 beta‐oestradiol)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: All doses of oestrogens
Number of subjects: 177
Study: 31128325

Group type: EXPERIMENTAL
Intervention: TBF conditioning regimen (thiotepa, busulfan, and fludarabine) with post-transplant cyclophosphamide (PT-Cy)
Number of subjects: 100
Study: 30054636

Group type: EXPERIMENTAL
Intervention: Positive CTC assay result (at least 1 CTC per 7.5 mL of blood)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: CTC-positive group
Number of subjects: 547

Group type: COMPARATOR
Intervention: CTC-negative group
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Positive CTC assay result
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Positive CTC assay result in hormone receptor-negative disease
Number of subjects: 547
Study: 26908305

Group type: EXPERIMENTAL
Intervention: Prolonged release (PR) oxycodone with naloxone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prolonged release (PR) oxycodone
Number of subjects: 0
Study: 25145426

Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional chemotherapy
Number of subjects: 0
Study: 22209655

Group type: EXPERIMENTAL
Intervention: Awareness of positive HCV status
Number of subjects: 1281

Group type: COMPARATOR
Intervention: Negative/unknown HCV status
Number of subjects: 1281
Study: 20538020

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 1318

Group type: EXPERIMENTAL
Intervention: Non-addicted smokers
Number of subjects: 1318

Group type: COMPARATOR
Intervention: Never-smoking controls
Number of subjects: 1318
Study: 17261429

Group type: COMPARATOR
Intervention: High-flux synthetic membranes
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Cellulosic low-flux membranes
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Low-flux semisynthetic membranes
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Low-flux synthetic membranes
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Cellulosic low-flux vs low-flux synthetic membranes
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Low-flux semisynthetic vs low-flux synthetic membranes
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Cellulosic low-flux vs low-flux semisynthetic membranes
Number of subjects: 648
Study: 15872132

Group type: EXPERIMENTAL
Intervention: Isoflurane (Group I, n = 15)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sevoflurane (Group S, n = 17)
Number of subjects: 32
Study: 12093837

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided catheter moulding
Number of subjects: 640

Group type: COMPARATOR
Intervention: Control group (clinical feel method)
Number of subjects: 640
Study: 10214534

Group type: EXPERIMENTAL
Intervention: Avitriptan 150 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sumatriptan 100 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Avitriptan 75 mg
Number of subjects: 20
Study: 8848532

Group type: EXPERIMENTAL
Intervention: Ro 41-3696 (1, 3, 5 and 10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ro 41-3696 (5 and 10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ro 41-3696 (up to 5 mg)
Number of subjects: 12
Study: 2088202

Group type: EXPERIMENTAL
Intervention: Magnesium-aluminum hydroxide (MAH) 15 ml
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CC) 5 ml
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ofloxacin alone
Number of subjects: 32
Study: 74281

Group type: EXPERIMENTAL
Intervention: BACON (bleomycin, adriamycin, CCNU, vincristine, mechlorethamine)
Number of subjects: 231

Group type: COMPARATOR
Intervention: NAC (mechlorethamine, adriamycin, CCNU)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: BACON (for PS 8-10)
Number of subjects: 231

Group type: COMPARATOR
Intervention: NAC (for PS 8-10)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: BACON (for PS 5-7)
Number of subjects: 231

Group type: COMPARATOR
Intervention: NAC (for PS 5-7)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: BACON (for PS 1-4)
Number of subjects: 231

Group type: COMPARATOR
Intervention: NAC (for PS 1-4)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Patients who responded or improved (regardless of PS)
Number of subjects: 231
Study: 31344520

Group type: EXPERIMENTAL
Intervention: Virtual Learning Collaborative (VLC) - 18-month intensive group-based with monthly learning sessions
Number of subjects: 48

Group type: COMPARATOR
Intervention: Individual technical assistance - four scheduled conference calls over 18 months
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Virtual Learning Collaborative (VLC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Individual technical assistance
Number of subjects: 48
Study: 28464343

Group type: EXPERIMENTAL
Intervention: Gaviscon Double Action (20 mL after meals and bedtime)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo (20 mL after meals and bedtime)
Number of subjects: 314
Study: 25410648

Group type: EXPERIMENTAL
Intervention: 2‐L polyethylene glycol with ascorbic acid (2‐L PEG/Asc)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Sodium picosulfate with magnesium citrate (SP/MC)
Number of subjects: 388
Study: 23799903

Group type: EXPERIMENTAL
Intervention: Buttonhole cannulation
Number of subjects: 104

Group type: COMPARATOR
Intervention: Rope-ladder cannulation
Number of subjects: 104
Study: 21316048

Group type: EXPERIMENTAL
Intervention: Anastrozole 5 mg
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Anastrozole 10 mg
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Anastrozole 20 mg
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Anastrozole 30 mg
Number of subjects: 194

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 50 mg/d
Number of subjects: 194
Study: 19231337

Group type: EXPERIMENTAL
Intervention: CRT on
Number of subjects: 15

Group type: COMPARATOR
Intervention: CRT off
Number of subjects: 15
Study: 16875507

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: All-round functional-skills training
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Both resistance and functional-skills training
Number of subjects: 157

Group type: COMPARATOR
Intervention: Educational control condition
Number of subjects: 157
Study: 12915798

Group type: EXPERIMENTAL
Intervention: Sucrose solution (2 mL)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Water (2 mL)
Number of subjects: 34
Study: 10852774

Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (40 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9024474

Group type: EXPERIMENTAL
Intervention: Cancer support groups (CSGs) with coaching
Number of subjects: 181

Group type: COMPARATOR
Intervention: Cancer support groups (CSGs) without coaching
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: CSGs (both with and without coaching)
Number of subjects: 181